News
MBQIF
0.700
NaN%
--
IBN ANNOUNCES LATEST EPISODE OF THE TECHMEDIAWIRE PODCAST FEATURING JUSTIN HANKA, CEO OF MINDBIO THERAPEUTICS CORP.
Reuters · 4d ago
MindBio develops AI voice model to predict fatigue, adds module to detection kiosks
PUBT · 5d ago
Weekly Report: what happened at MBQIF last week (0504-0508)?
Weekly Report · 5d ago
MindBio Develops Fatigue Prediction Model using Speech Analytics and AI
Barchart · 5d ago
MindBio develops cross-language AI speech model detecting drug, alcohol intoxication
PUBT · 05/05 13:31
MindBio Develops Cross-Language AI Speech Analytics Capability for Intoxication Detection Patent applications filed in 15 world firsts using Voice and AI
Barchart · 05/05 08:31
Weekly Report: what happened at MBQIF last week (0427-0501)?
Weekly Report · 05/04 10:43
MindBio says voice AI model predicts drug, alcohol intoxication using 50 million data points
PUBT · 04/29 11:21
MindBio Files Patent Applications in 15 World Firsts
Barchart · 04/29 06:06
Weekly Report: what happened at MBQIF last week (0420-0424)?
Weekly Report · 04/27 10:47
Weekly Report: what happened at MBQIF last week (0413-0417)?
Weekly Report · 04/20 10:41
MindBio appoints Venture Liquidity Providers as market maker, pays $5,000 monthly
PUBT · 04/15 02:00
MindBio Appoints Market Maker Venture Liquidity Providers
Barchart · 04/14 20:59
MindBio corrects private placement disclosure, reports $74,984 finder’s fees and 124,973 warrants
PUBT · 04/13 12:34
Weekly Report: what happened at MBQIF last week (0406-0410)?
Weekly Report · 04/13 10:47
Weekly Report: what happened at MBQIF last week (0330-0403)?
Weekly Report · 04/06 10:47
MindBio Therapeutics closes upsized private placement raising $1.4 million
Reuters · 04/02 07:26
MindBio Therapeutics closes upsized private placement for gross proceeds of $1.4 million
Reuters · 04/01 19:45
Weekly Report: what happened at MBQIF last week (0323-0327)?
Weekly Report · 03/30 10:47
Weekly Report: what happened at MBQIF last week (0316-0320)?
Weekly Report · 03/23 10:42
More
Webull provides a variety of real-time MBQIF stock news. You can receive the latest news about Mindbio Therapeutics Corp through multiple platforms. This information may help you make smarter investment decisions.
About MBQIF
MindBio Therapeutics Corp. is a clinical-stage biopharmaceutical company. It creates novel and emerging treatments for mental health conditions and is conducting take-home Microdosing (MB22001) human clinical trials. MB22001 is its lead candidate drug, a titratable form of Lysergic Acid Diethylamide designed for take-home microdosing. It is focused on microdosing of psychedelic medicines and is advancing its drug and technology through clinical trials. It develops a multidisciplinary platform for developing treatments and is involved in psychedelic medicine development and digital therapeutics, has completed Phase I clinical trials in 80 healthy participants and has completed Phase II clinical trials in patients with Major Depressive Disorder. Underway are Phase IIB trials, one in cancer patients experiencing existential distress and another in patients with Major Depressive Disorder. It invests in research that forms the basis for developing novel and clinically proven treatments.